The (13)(10/3) injectable-grade multivitamin premix addressed in this application index is supplied as a low-bioburden, pyrogen-controlled, multi-component vitamin active pharmaceutical ingredient for downstream pharmaceutical dosage manufacture. The designation (13)(10/3) identifies the total vitamin count and the supplier’s partition code for water-soluble and fat-soluble fractions; exact assay limits, residual solvent profile, and microbial specification are defined in the active substance dossier. Because the material carries parenteral-grade specifications, downstream manufacture is controlled for bacterial endotoxins according to USP <85>, subvisible particulate matter according to USP <788>, and sterility according to USP <71> where the finished dosage form is aseptic. The same material can be incorporated into oral solid, granule, and oral liquid dosage forms provided that the downstream process is validated for homogeneous distribution of all thirteen components and that moisture, oxygen, light, and trace-metal exposure are controlled. The six scenarios below are restricted to pharmaceutical manufacturing routes with established technical feasibility: hospital parenteral nutrition compounding, lyophilized injectable powder, oral tablet and capsule granulation, effervescent granules, oral liquid multivitamin drops, and aseptic single-dose injectable vial filling.

In hospital pharmacy sterile compounding of adult total parenteral nutrition (TPN) admixtures, the injectable-grade multivitamin premix is added to the dextrose–amino acid base solution before the lipid emulsion is incorporated. The governing industry standard is USP Chapter <797>, which assigns this operation to low-risk or medium-risk compounded sterile preparation categories depending on batch size and number of components; the compounding environment must be an ISO Class 5 laminar airflow workbench located within an ISO Class 7 buffer area, and compounding personnel must pass media-fill testing at intervals not exceeding 12 months. Typical addition ratios follow the labeled adult daily dose of 10 mL or one single-dose unit into a final TPN volume of 1,000–2,500 mL; pediatric and neonatal dosing is weight-based at 1.5 mL/kg up to 5 mL/day, but the exact labeled dose, vitamin A palmitate-to-retinol equivalence, and pediatric allowance must be confirmed against the supplier’s certificate of analysis and drug master file because vitamin assay limits vary among pharmacopeial standards. The order of addition is a critical processing parameter: the vitamin concentrate must first be diluted below 2% w/v in the amino acid/dextrose admixture before trace element injections containing zinc, copper, or selenium are introduced, because undiluted ascorbic acid and riboflavin accelerate the oxidative degradation of thiamine and can reduce metal ions to non-bioavailable species. The concentrated vitamin solution should also not be added directly to lipid emulsion because the high aqueous osmotic pressure and altered pH can destabilize lipid globules. The finished admixture is not terminally sterilized; it is aseptically transferred into ethylene-vinyl acetate (EVA) or polyolefin TPN bags and protected from light during administration because riboflavin and retinol degrade under fluorescent light. Beyond-use dating is assigned according to USP <797> risk level: 9 days at 2–8°C for low-risk batches with sterile components, or 24 h at controlled room temperature for compounded sterile products prepared in less controlled environments. Terminal product types include adult central-line TPN bags, neonatal peripheral parenteral nutrition bags, and vitamin additive syringes for home infusion. Published stability data for this specific (13)(10/3) premix in high-calcium TPN formulations are limited; therefore compatibility with organic phosphate and calcium gluconate must be re-verified when the total calcium-to-phosphate ratio and amino acid source change.

How Does the Premix Support Lyophilized Injectable Dose Construction?

Lyophilized injectable multivitamin products are manufactured by reconstituting the premix in Water for Injection to a total solids content of 5–20% w/v, with the exact target determined by the required cake thickness and the solubility limit of riboflavin phosphate. The formulation typically includes mannitol or glycine as a crystallizing bulking agent at 30–70% of total solids, sodium hydroxide or citric acid for pH adjustment to 5.5–7.0, and disodium edetate at 0.01–0.05% w/v as a metal chelator to suppress copper- and iron-catalyzed ascorbate oxidation. Riboflavin phosphate solubility in Water for Injection is approximately 9 mg/mL at 25°C; the premix is therefore diluted to keep riboflavin below 2 mg/mL to prevent precipitation during sterile filtration and filling. The bulk solution is filtered through a 0.22 µm polyethersulfone membrane filter under nitrogen pressure, filled into amber Type I glass vials, and partially stoppered under Grade A unidirectional airflow in a Grade B background. Lyophilization cycle parameters include shelf pre-cooling to -45°C, primary drying at -20°C to -10°C with chamber pressure 0.05–0.10 mbar for 24–48 h, and secondary drying at 25–35°C until residual moisture is below 2.0%. Vitamin A palmitate and phytonadione are light-sensitive and oxygen-sensitive; the vial headspace is therefore flushed with nitrogen to residual oxygen below 2.0% before stoppering. Industry standards governing the process include EU GMP Annex 1 for aseptic processing, USP <1> for injectable dosage forms, USP <71> for sterility testing, USP <85> for bacterial endotoxins, and USP <921> for Karl Fischer water content. Terminal product types are single-dose lyophilized vials for reconstitution with 5 mL or 10 mL of sterile water or 0.9% sodium chloride injection, yielding a clear yellow solution for intravenous admixture. Published data for this specific (13)(10/3) premix are limited; the lyophilization parameters are derived from general parenteral vitamin development literature and must be confirmed through a product-specific design-of-experiment program.

Tablet and Capsule Granulation Boundaries for B-Vitamin-Loaded Formulations

When the injectable-grade premix is utilized for oral solid dose manufacture, the particle-size distribution and hygroscopicity of the raw blend determine whether direct compression or wet granulation is feasible. Riboflavin and thiamine mononitrate exhibit cohesive flow; batch-to-batch variance in angle of repose from 35° to 45° has been documented when unconditioned premix is stored above 60% relative humidity, which can cause die-fill variation exceeding 3% RSD on rotary tablet presses operating at 70–100 rpm. Pre-drying in a vacuum dryer at 40°C for 4–6 h is required if raw premix storage relative humidity exceeds 60%. To stabilize flow and content uniformity, the premix is pre-sieved through an 840 µm screen and dry-blended with microcrystalline cellulose and dicalcium phosphate dihydrate in a bin blender at 12–18 rpm for 20 min. Addition ratio commonly ranges from 5% to 25% w/w of the tablet core, with the remainder comprised of diluent, disintegrant such as croscarmellose sodium at 2–5% w/w, binder such as povidone K30 at 2–4% w/w when wet granulated, and lubricant such as magnesium stearate at 0.5–1.0% w/w. Over-lubrication above 1.5% w/w or blending beyond 5 min after magnesium stearate addition can retard dissolution of B vitamins by forming a hydrophobic film on granule surfaces. Wet granulation with an aqueous povidone solution is preferred when ascorbic acid content exceeds 100 mg per dose because ascorbic acid exhibits poor compaction properties; however, granule water activity must be kept below 0.2 during drying to limit vitamin C degradation. The dried granules are milled through a 1.0 mm screen and compressed to tablet hardness of 60–120 N using a rotary tablet press with a compression force of 8–18 kN. Direct compression is reserved for formulations with vitamin premix below 10% w/w and excipients with D50 between 80 µm and 150 µm. Industry standards include USP <711> for dissolution testing, USP <701> for disintegration, USP <905> for content uniformity, and ICH Q3D for elemental impurities. Terminal product types are film-coated oral tablets, chewable tablets, and two-piece hard gelatin or hydroxypropyl methylcellulose capsules.

For effervescent oral granules and sachets, the premix is processed under low-humidity conditions because the carbonate–acid reaction system is incompatible with free moisture. A typical formulation uses citric acid and sodium bicarbonate in a molar ratio of 1:3 to achieve a pH of 3.5–5.0 upon reconstitution in 200 mL of water, while the vitamin premix is added at 2–8% w/w of the dry granule mass to preserve dissolution clarity and limit vitamin degradation by locally generated carbon dioxide. The manufacturing route is dry granulation by slugging or roll compaction rather than wet granulation; granules are milled to a particle-size distribution with D10 greater than 100 µm, D50 between 250 µm and 600 µm, and D90 below 1,000 µm to ensure rapid dispersion. Production humidity is maintained below 25% RH; packaging in Alu/Alu foil laminate with a desiccant sachet is required to maintain sachet moisture vapor transmission rate below 0.05 g/m²/day. Ascorbic acid and cyanocobalamin in the granule matrix degrade when residual moisture exceeds 1.5%; batch records therefore specify Karl Fischer moisture below 1.0% before filling. Compliance for effervescent granules is assessed using USP <701> for disintegration time, with complete dispersion expected within 5 minutes in 15°C water, USP <601> for powder properties where applicable, and ICH Q1A(R2) for stability. Terminal product types are single-dose effervescent sachets, bulk oral powders for reconstitution, and pediatric sprinkle granules co-packed with metered dosing scoops.

Oral Liquid Multivitamin Drops and Syrups—Oxygen, pH, and Solubilizer Constraints

In aqueous oral liquids, the primary technical constraint is the incorporation of fat-soluble vitamins—retinol, cholecalciferol, alpha-tocopherol acetate, and phytonadione—into a water-miscible vehicle without phase separation or oxidative degradation. The premix is separated into a water-soluble phase and a fat-soluble phase prior to compounding. The fat-soluble phase is pre-emulsified with polysorbate 80 at a ratio of 1:5 to 1:20, vitamin oil to solubilizer, and may include alpha-tocopherol acetate as an antioxidant at 0.1–0.5% w/w; the aqueous phase contains purified water, glycerol or sorbitol at 10–30% w/v, sodium benzoate at 0.1–0.2% w/v, and disodium edetate at 0.01–0.05% w/v. Addition ratio of the multivitamin premix typically ranges from 0.5% to 5.0% w/v depending on whether the product is a concentrated infant drop or an adult syrup; the upper limit is controlled by the solubility of riboflavin phosphate and by the taste threshold of thiamine hydrochloride, which imparts a bitter note above 1 mg/mL. The two phases are combined under vacuum high-shear mixing at 3,000–8,000 rpm and the pH is adjusted to 3.8–5.0 with a citric acid/sodium citrate buffer to optimize ascorbic acid stability and preservative activity. Dissolved oxygen is reduced by nitrogen sparging to below 0.5 ppm before filling into amber PET or Type III glass bottles with child-resistant dropper closures. The critical stability indicators are ascorbic acid retention, appearance of haze, and antimicrobial effectiveness. Industry standards include USP <51> for antimicrobial effectiveness testing, USP <791> for pH, and ICH Q1C for stability of oral liquids. Terminal product types are pediatric oral drops in 15 mL and 30 mL dropper bottles, adult multivitamin syrup in 100 mL and 200 mL bottles, and unit-dose oral ampoules for hospital enteral administration.

When Single-Dose Injectable Vials Are Aseptically Filled from the 13-Vitamin Premix

Aseptic filling of ready-to-use injectable multivitamin solution uses the same premix as the lyophilized route but omits the freeze-drying step. The bulk solution is prepared in a closed stainless steel vessel under nitrogen, with Water for Injection, premix, and osmolality-adjusting excipients such as mannitol or sodium chloride to achieve an osmolality of 280–320 mOsm/kg. Addition ratio is determined by the labeled unit dose: for an adult single-dose 10 mL vial, the premix is reconstituted to contain the daily reference intake of each vitamin, which translates to a total dissolved solids load of 20–60 mg/mL depending on the supplier’s active content. The solution is filtered through 0.22 µm hydrophilic membrane filters and aseptically filled into amber Type I glass ampoules or vials under Grade A unidirectional airflow in a Grade B background. Because thiamine hydrochloride degrades above pH 5.0 and ascorbic acid degrades below pH 4.5, the pH is controlled at 5.0–6.5 using a citrate-phosphate buffer; oxygen is excluded by nitrogen purging to residual headspace oxygen below 1.5%. Terminal sterilization by moist heat is generally not feasible due to thermal degradation of cyanocobalamin and thiamine; therefore, the process relies entirely on aseptic processing. Industry standards are EU GMP Annex 1, USP <1>, USP <71>, USP <85>, USP <788> for subvisible particulates, and USP <790> for visible particulates. Terminal product types are ready-to-use single-dose ampoules, single-dose vials for intramuscular or intravenous use, and pre-filled syringes for hospital automated dispensing cabinets.